EDINBURGH UK – Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the
Edinburgh and Cambridge, UK, – Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered into a worldwide drug discovery collaboration agreement with
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug
EDINBURGH, UK – Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment
Bonney brings over 30 years of life sciences industry leadership experience as company advances its covalent chemistry platform for targeted protein degradation and beyond CAMBRIDGE,
ATLANTA, GA — Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the closing of
Edinburgh UK – Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment
Please see the article here for a Q+A interview with Dunad CEO Pearl Huang in Nature Reviews Drug Discovery.
NT-0796 successfully completes Phase 1 study, demonstrating blood-brain barrier penetration and reduced inflammatory biomarkers supporting advancement in neuroinflammatory and peripheral inflammatory diseases Second clinical candidate